T1	Condition 12 33	respiratory disorders
T2	Condition 37 46;53 74	signs for respiratory disorders
T3	Condition 81 87	asthma
T4	Condition 89 100	lung cancer
T5	Condition 102 113	sarcoidosis
T6	Condition 115 127	tuberculosis
T7	Condition 129 142	lung fibrosis
T8	Condition 144 159	cystic fibrosis
T9	Condition 161 175	bronchoectasis
*	OR T3 T4 T5 T6 T7 T8 T9
T10	Scope 81 175	asthma, lung cancer, sarcoidosis, tuberculosis, lung fibrosis, cystic fibrosis, bronchoectasis
*	OR T1 T2
T11	Scope 12 74	respiratory disorders or signs for other respiratory disorders
R1	Subsumes Arg1:T11 Arg2:T10	
T12	Condition 208 228	inflammatory disease
T13	Condition 241 245	COPD
T14	Condition 252 272	rheumatoid arthritis
T15	Condition 277 305	systemic lupus erythematosus
*	OR T14 T15
T16	Negation 230 240	other than
R2	Has_negation Arg1:T13 Arg2:T16	
T17	Condition 330 359	alpha-1-antitrypsin deficient
T18	Procedure 392 404	lung surgery
T19	Procedure 411 425	lung resection
T20	Procedure 436 465	lung volume reduction surgery
T21	Procedure 467 482	lung transplant
*	OR T20 T21
R4	Subsumes Arg1:T18 Arg2:T19	
T22	Procedure 510 517	surgery
T23	Observation 496 505	scheduled
R5	AND Arg1:T23 Arg2:T22	
T24	Drug 531 554	medication from Visit 1
T25	Drug 629 657	monoamine oxidase inhibitors
T26	Drug 662 687	tricyclic antidepressants
T27	Drug 693 702	ritonavir
T28	Drug 720 749	cytochrome P450 3A4 inhibitor
*	OR T25 T26 T27
R6	Subsumes Arg1:T27 Arg2:T28	
T29	Scope 629 750	monoamine oxidase inhibitors and tricyclic antidepressants, and ritonavir (a highly potent cytochrome P450 3A4 inhibitor)
R7	Subsumes Arg1:T24 Arg2:T29	
T30	Procedure 783 814	prophylactic antibiotic therapy
T31	Procedure 772 779;796 814	chronic antibiotic therapy
*	OR T31 T30
T32	Condition 826 846	uncontrolled disease
T33	Condition 866 889	psychological disorders
R8	Subsumes Arg1:T32 Arg2:T33	
T34	Condition 1010 1017;1035 1040	alcohol abuse
T35	Condition 1019 1023;1035 1040	drug abuse
T36	Condition 1027 1040	solvent abuse
*	OR T34 T35 T36
T37	Condition 1113 1129	drug sensitivity
T38	Condition 1156 1173	allergic reaction
T39	Drug 1177 1192	corticosteroids
T40	Drug 1196 1206	salmeterol
T41	Scope 1177 1206	corticosteroids or salmeterol
*	OR T39 T40
*	OR T37 T38
T42	Scope 1113 1173	drug sensitivity or clinically significant allergic reaction
R9	Has_scope Arg1:T42 Arg2:T41	
T43	Condition 1228 1245	COPD exacerbation
T44	Qualifier 1221 1227	severe
T45	Qualifier 1209 1217	Moderate
*	OR T45 T44
T46	Scope 1209 1227	Moderate or severe
R10	Has_scope Arg1:T43 Arg2:T46	
T47	Drug 1257 1272	corticosteroids
T48	Drug 1296 1311	corticosteroids
T49	Qualifier 1276 1292	increased dosage
R11	Has_qualifier Arg1:T48 Arg2:T49	
R12	AND Arg1:T48 Arg2:T47	
T50	Drug 1319 1330	antibiotics
T51	Visit 1334 1349	hospitalization
*	OR T48 T50 T51
T52	Scope 1257 1349	corticosteroids or increased dosage of corticosteroids and/or antibiotics or hospitalization
R13	Has_scope Arg1:T43 Arg2:T52	
T53	Temporal 1351 1386	within the 4 weeks prior to Visit 1
T54	Condition 1388 1421	Lower respiratory tract infection
T55	Temporal 1422 1457	within the 4 weeks prior to Visit 1
T56	Condition 1461 1469	Pregnant
T57	Condition 1473 1482	lactating
*	OR T56 T57 T59
T58	Person 1483 1489	female
T59	Condition 1504 1526	childbearing potential
T60	Person 1494 1500	female
R14	AND Arg1:T12 Arg2:T13	
T61	Scope 252 305	rheumatoid arthritis and systemic lupus erythematosus
T62	Scope 208 245	inflammatory disease, other than COPD
R15	Subsumes Arg1:T62 Arg2:T61	
T63	Scope 436 482	lung volume reduction surgery, lung transplant
R3	Subsumes Arg1:T19 Arg2:T63	
*	OR T18 T22
R16	Has_temporal Arg1:T43 Arg2:T53	
T64	Reference_point 1379 1386	Visit 1
R17	Has_index Arg1:T53 Arg2:T64	
T65	Reference_point 1450 1457	Visit 1
R18	Has_index Arg1:T55 Arg2:T65	
R19	Has_temporal Arg1:T54 Arg2:T55	
T66	Non-representable 1529 1764	Subject is a participating investigator, sub-investigator, study coordinator, or other employee of a participating investigator, or is an immediate family member of the before mentioned. Subject is an employee of GlaxoSmithKline (GSK).
T67	Observation 1774 1819	participated in an investigational drug study
T68	Temporal 1820 1851	within 30 days prior to Visit 1
T69	Reference_point 1844 1851	Visit 1
R20	Has_index Arg1:T68 Arg2:T69	
R21	Has_temporal Arg1:T67 Arg2:T68	
T70	Qualifier 196 207	significant
R22	Has_qualifier Arg1:T62 Arg2:T70	
T71	Qualifier 321 329	severely
R23	Has_qualifier Arg1:T17 Arg2:T71	
T72	Observation 1043 1053	History of
T73	Condition 1054 1064	depression
R24	Has_temporal Arg1:T73 Arg2:T72	
T74	Non-representable 962 996	in the opinion of the investigator
T75	Scope 1010 1040	alcohol, drug or solvent abuse
R25	AND Arg1:T75 Arg2:T74	
